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Abstract
Backgrounds Obstructive sleep apnea (OSA) is common in
patients on hemodialysis, but its correlation with chronic kid-
ney disease (CKD) is not clear. We aimed to clarify the rela-
tionship between OSA without hypertension or diabetes and
incidence of CKD in Taiwan.
Methods This population-based cohort study consisted of pa-
tients with newly diagnosed OSA between 2000 and 2009.
The comparison cohort was matched for age, sex, diabetes
mellitus, and hypertension. All subjects previously diagnosed
with acute or chronic kidney disease were excluded. The pri-
mary end point was newly diagnosed CKD.
Results We identified 6866 subjects with OSA during the 10-
year study period. The median duration until development of
CKD in the OSA cohort was 3.2 years, 2.5 months earlier than
that in the non-OSA cohort. After exclusion of hypertension
and diabetes, 4319OSA patients was identified and the hazard
ratio (HR) of CKD with OSA was 1.37 (95 % confidence
interval [CI], 1.05–1.77; p = 0.019). In the subgroup analysis,
an increased incidence of CKD in OSAwas observed in wom-
en (HR, 1.41; 95 % CI, 1.12–1.78; p = 0.0036).
Conclusions This longitudinal population-based cohort study
provides evidence that patients with OSA even without dia-
betes or hypertension are at higher risk of developing CKD
over the next 3 years and nearly 2.5 months earlier than the
non-OSA cohort, particularly women.
Keywords Obstructive sleep apnea . Kidney dysfunction .
Diabetes . Hypertension
Introduction
Obstructive sleep apnea (OSA) is a disorder that affects
2–4 % of adults in the general population of Taiwan and
worldwide [1, 2]. OSA patients increase hypertension and
diabetes melli tus risk [3–6]. Cardiovascular and
neurocognitive complications are the most common and
severe consequences noted in these patients [7]. The un-
derlying mechanisms are complex and involve oxidative
stress and inflammation, sympathetic tone stimulation,
and fluid shifting, which may negatively affect kidney
function; thus, it is not surprising that OSA is highly
prevalent among patients on hemodialysis [8–10].
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Chronic kidney disease (CKD) affects 10–13% of the gen-
eral population in Taiwan and is associated with substantial
morbidity and mortality rates, particularly with regard to car-
diovascular diseases and end-stage kidney disease [11].
Diabetes and hypertension are the two major risk factors for
CKD [12–14]. Our previous study found that patients with
OSAwithout diabetes and hypertension have a higher preva-
lence of impaired renal function [15]. Sim et al. reported an
association of OSA and CKD in cross-sectional study and
Ahmed et al, reported that nocturnal hypoxia may have a
higher prevalence for loss of kidney function [16–18].
TAHRANI reported a small diabetes cohort that higher prev-
alence of OSAwill enhance the declaration of eGFR in 2-year
follow up [19]. Molnar reported higher incidence of CKD
associated to OSA veterans in a 3 million USA cohort sub-
group analysis [20]. Recently, Lee reported OSA patients pre-
disposing to the development of CKD and end-stage renal
disease (ESRD) [21]. However, the interaction between
CKD and pure OSA without hypertension or diabetes is not
confirmed due to selection bias. To clarify the relationship of
OSA and CKD, we aimed to design this retrospective longi-
tudinal population-based case-control cohort study especially
focused on pure OSAwithout diabetes or hypertension.
Materials and methods
Data source
This was a retrospective cohort study that used the
Longitudinal Health Insurance Database 2000 (LHID2000)
in Taiwan, a subset of the National Health Insurance
Research Database (NHIRD) (http://nhird.nhri.org.
tw/date_01.html), containing all original claims data for one
million randomly sampled insured patients in 2000. The
NHIRD comprises medical and pharmacy claims including
inpatient and outpatient diagnoses and procedures based on
the International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM). The data are considered
reasonably representative of Taiwan residents, since >99 % of
Taiwan’s population was enrolled in the NHI program [22].
All personal identifiers were encrypted by the Bureau of
NHI prior to being released to researchers. The institutional
review board of Chang Gung Memorial Hospital approved
this retrospective study (IRB number 101-5057B) and waived
the requirement for informed consent.
Study and comparison cohort
The study cohort consisted of 6866 adult patients (aged
≥18 years) with newly diagnosed OSA between 2000 and
2009. A diagnosis of OSA included sleep apnea with
hypersomnia (ICD-9-CM 780.53), sleep apnea with insomnia
(ICD-9-CM 780.51), and sleep apnea unspecified (ICD-9-CM
780.57) as previously reported [23]. Due to Taiwan’s medical
coverage system, there must be a diagnosis for further disease
checkup in clinic; we only enrolled patients with OSA diag-
nosis completing three or more outpatient verification visits
within 1 year or those who had been hospitalized with a diag-
nosis of OSA. The index date for each patient was that of the
first OSA diagnosis.
Acute or chronic kidney disease diagnosis is based on the
ICD-9-CM code including 581 (nephritic syndrome), 582
(chronic glomerulonephritis), 583 (nephritis and nephropathy
not specified as acute or chronic), 584 (acute kidney failure),
and 585 (chronic kidney disease) OSA patients, and patients
who were previously diagnosed with acute or CKD (ICD-9-
CM 581-585) before the index date were excluded from the
analyses.
The comparison cohort consisted of adults (age ≥18 years)
without OSA (non-OSA) who were randomly selected from
the remaining individuals after excluding any diagnosis with
OSA in the LHID2000 database. All non-OSA subjects were
matched with the study cohort for age, sex, diabetes (ICD-9-
CM 250), hypertension (ICD-9-CM 401.0, 401.1, and 401.9),
and index year. None of the non-OSA subjects had been pre-
viously diagnosed with acute or CKD (ICD-9-CM 581-585)
before the index year. All study and comparison cohort mem-
bers were followed up for at least 1 year. Details are described
on the right of the flow chart (Fig. 1, right side) and Table 1.
Events of chronic kidney disease
The primary end point was newly diagnosed CKD during the
study period. The CKD diagnosis included 582 (chronic glo-
merulonephritis), 583 (nephritis and nephropathy not speci-
fied as acute or chronic), and 585 (chronic kidney disease)
as previous reported on AJKD, and the nephritic syndrome
was excluded due to the urine protein loss could not be con-
firmed from the database system. Newly diagnosed cases of
CKD were identified as those who visited the outpatient care
clinic or were hospitalized with a diagnosis of CKD (ICD-9-
CM 582, 583, 585). However, to eliminate enrollment bias,
we excluded the CKD episodes that occurred during the first
year of follow up in this cohort study.
Statistical analyses
For this analysis, follow-up time began on the index date of
OSA and ended at the time of the CKD diagnosis, when the
patient quit insurance, or on January 31, 2011, whichever
came first. The descriptive results were displayed by the num-
ber of baseline characteristics among the OSA and non-OSA
cohorts. The incidence of CKD was calculated based on
person-years of follow-up for 2000–2011. Person-years of
follow-up were estimated for each individual from the index
86 Sleep Breath (2017) 21:85–91
date until the date of the CKD diagnosis, when the patient quit
insurance, or on January 31, 2011. Kaplan-Meier methods and
the log-rank test were used to examine the cumulative proba-
bility of CKD development according to the presence of OSA.
The Cox proportional hazards models were used to analyze
the association of baseline OSAwith the risk of CKD with or
without adjustment for age, sex, diabetes, and hypertension at
baseline. The proportional hazards assumption was not violat-
ed, and hazard ratios (HRs) with 95 % confidence intervals
(CIs) were calculated. Two-tailed tests were used and p values
<0.05 were considered significant. The statistical analyses
were performed using SAS version 9.2 (SAS Institute Inc.,
Cary, NC, USA) and STATA version 14.0 (STATA Corp,
College Station, TX, USA).
Results
The baseline demographics and clinical characteristics of the
OSA and non-OSA cohorts are given in Table 1. There were
no important differences between cohorts as expected due to
the sample matching. We identified 6866 subjects with OSA
who were followed up for a median of 4.4 years (total person-
years = 33,402.5). In the non-OSA cohort, 34,330 subjects
werematched to the OSA cohort and followed up for a median
of 4.4 years (total person-years = 167,146.1). Of the 41,196
study subjects, 1082 reported CKD during the course of the
study: 215 in the OSA cohort (median follow-up years, 3.2)
and 867 in the non-OSA cohort (median follow-up years, 3.4).
Patients in the OSA cohort developed CKD 2.5 months earlier
than those in the non-OSA cohort did. The crude CKD event
Follow-up to 2011 
OSA paents in 
2000-2009 (N=8,279) 
OSA cohort (N=6,866) 
CKD (N=215) 
Exclusion criteria of OSA paents (N=1,413) 
1. Aged <18 years 
2. with duraon of follow-up < 1 year 
3. with CKD before OSA diagnosis 




Exclusion criteria of 
non-OSA cohort the same 
as those of OSA paents 
Fig. 1 Flow chart of
ascertainment of OSA and non-
OSA cohort
Table 1 Characteristic of matching variables in OSA and non-OSA
cohorts at baseline of follow-up
OSA (%) Non-OSA (%)
(N = 6866) (N = 34,330)
Age at baseline
18–29 949 (13.82) 4745 (13.82)
30–39 1460 (21.26) 7300 (21.26)
40–49 1714 (24.96) 8570 (24.96)
50–59 1496 (21.79) 7480 (21.79)
60–69 719 (10.47) 3595 (10.47)
≥70 528 (7.69) 2640 (7.69)
Sex
Male 4311 (62.79) 21,555 (62.79)
Female 2555 (37.21) 12,775 (37.21)
Diabetes
Yes 1195 (17.40) 5975 (17.40)
No 5671 (82.60) 28,355 (82.60)
Hypertension
Yes 2070 (30.15) 10,350 (30.15)
No 4796 (69.85) 23,980 (69.85)
OSA obstructive sleep apnea
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rate was higher for patients with OSA (23.3 outcomes per
1000 person-years) than for those without OSA (19.6 out-
comes per 1000 person-years). With the Cox proportional
hazards model, estimated HR (95 % CI) for risk of CKD with
OSA versus non-OSA was 1.24 (1.07–1.44; p = 0.0045)
(Table 2). After adjustment for age, sex, hypertension, and
diabetes, the association between OSA and first CKD event
remained significant. After excluding the confounding factors
of CKD, hypertension, and diabetes, the risk of incident CKD
persisted in the OSA cohort (HR, 1.37; 95 % CI, 1.05–1.77;
p = 0.019) (Table 3). Figure 2 shows the cumulative probabil-
ity of CKD development by OSA presence. The OSA cohort
had higher cumulative incidence of CKD. The difference was
statistically significant according to the log-rank test in com-
parison with the non-OSA cohort (p = 0.0045).
Subgroup analyses
Table 3 also shows the relationship between OSA and the
incidence of CKD in patients aged 18–39 years and ≥40 years
as well as in men and women separately. An increase in the
HR of the incidence of CKD due to OSA was observed in
persons ≥40 years of age (HR, 1.21; 95 % CI, 1.03–1.42;
p = 0.022) and borderline significant in persons 18–39 years
of age (HR, 1.52; 95 % CI, 1.01–2.28; p = 0.045). Similarly,
the risk of developing CKD was higher for women with OSA
than for those without it (HR, 1.41; 95 % CI, 1.12–1.79;
p = 0.0039). However, the risk of developing CKD among
men with OSAwas not significant.
Discussion
Our group is the first to report a correlation between CKD and
OSA severity in 40 OSA patients without hypertension and
diabetes [15]. Later, Y et al. reported the association with a
worse estimated glomerular filtration rate in 100 patients with
CKD stage 3–4 and OSA [24, 25]. However, all these are
small prevalence studies. Previous large longitudinal OSA
cohort studies such as the Sleep Heart Health Study (SHHS)
and Wisconsin Sleep Cohort Study (WSS) reported the asso-
ciated adverse outcomes of hypertension, stroke, and mortal-
ity but not CKD outcomes [3, 4, 26]. Lee reported the predis-
posing association between OSA and CKD recently using the
same Taiwan’s medical insurance database. However, due to
statistic limitation, the selection bias about hypertension and
diabetes cannot be clarified in their follow-up model. Also, the
importance at young adult is difficult to evaluate due to the
age selection (over 30 years old) and excluded from their
study population. Our study from Taiwan’s one million med-
ical insurance databases is the first large population-based
cohort study to use a prospective statistical model to identify
the increasing 1.37-fold incidence of CKD risk in pure OSA
patients in Taiwan after excluding hypertension and diabetes.
In addition to a higher risk of developing CKD, the OSA
cohort developed CKD 2.5 months earlier than the non-OSA
cohort did.
Previous studies have mounting evidences of OSA accel-
erating diabetes nephropathy [19, 27], and a small study and
case report showed that CPAP treatment may improve protein-
uria in diabetes patients [28, 29]. There are many factors in-
cluding sleep cycle and the renin-angiotensin-aldosterone sys-
tem [30, 31], intermittent hypoxia-induced endothelial dys-
function and artery stiffness [32–34], and renal tubular
dysfunction-related nocturnal natriuresis [29, 35, 36] that
may impact kidney function from OSA. In recent reviews,
Dr Adeseun emphasizes intermittent hypoxia and sleep
fragmentation-related kidney injury mechanism and possible
more direct insults from intermittent hypoxia to CKD [37]. Dr
Hanly reported more evidences suggest that OSA having di-
rect impact on CKD especially from direct effect of intrarenal
hypoxia and activation of the systemic and renal renin-
angiotensin system but need further studies [38]. From the
finding of our study, the evidence is obvious that OSA patients
have impact on the deterioration of kidney function in a 12-
year follow up. It is important to emphasize regularly
checking the renal function and even the early renal injury
markers in OSA patients, especially on the patients coexisting
with other risk factors such as diabetes or hypertension. It is
also important to emphasize the treatment of OSA such as
CPAP therapy on the view of preventing the CKD.
Second, a difference in the outcomes between the sexes
was noted by the SHHS and WSS, with a higher risk in men
for stroke and hypertension, but all studies enrolled only pa-
tients >40 years with OSA. We found that the incidence of
CKD was persistently high with a 1.5-fold risk in the OSA
group aged 18–39 years, which has not been reported previ-
ously and needs further verification and evaluation. Finally,
Table 2 Hazard ratio and 95 %
confidence interval of incident
CKD associated with OSA





OSA 6866 215 23.3 1.24 (1.07, 1.44) 0.0045
Non-OSA 34,330 867 19.6 Reference
OSA obstructive sleep apnea, CKD chronic kidney disease
88 Sleep Breath (2017) 21:85–91
although the same trend was seen, the risk of CKD was sta-
tistically confirmed in women only. This interesting finding
may be impacted by other inaccessible factors from this study,
such as Chinese herb drug usage including aristolochic acid,
which requires further verification [39].
However, there are limitations relating to the population-
based ICD-9 code-recording database itself and others [19,
22]. First, environmental and risk factors such as aging,
smoking, obesity, and metabolic syndrome could not be iden-
tified from the database and adjusted for in the analysis.
Second, the exact detailed laboratory data such as
polysomnography information and proteinuria severity
were inaccessible. Therefore, this study reported results
from patients with OSA based on clinical diagnosis
alone. This may underestimate the effects of severe
OSA on CKD development. A prospective OSA cohort
study is needed in the future to clarify the relationship
between OSA severity and CKD.
In conclusion, this longitudinal population-based cohort
study using a statistically prospective model provides the first
evidence that patients with pure OSAwithout hypertension or
diabetes are at higher risk of developing CKD over the next
3 years and nearly 2.5 months earlier than the non-OSA co-
hort, particularly women.
Table 3 Hazard ratios of CKD
for OSA compared with non-
OSA by cohort without diabetes












OSA 4319 72 12.8 1.37 (1.05, 1.77) 0.019
Non-OSA 21,595 264 9.6
Male
OSA 4311 124 21.7 1.14 (0.94, 1.39) 0.19
Non-OSA 21,555 542 19.8
Female
OSA 2555 91 26.1 1.41 (1.12, 1.78) 0.0036
Non-OSA 12,755 325 19.3
Aged 18–39 years
OSA 2481 39 9.0 1.52 (1.01, 2.28) 0.046
Non-OSA 12,405 102 6.3
Aged ≥40 years
OSA 4457 185 31.3 1.21 (1.03, 1.42) 0.022
Non-OSA 22,285 768 27.0
OSA obstructive sleep apnea, CKD chronic kidney disease
Fig. 2 The cumulative
probability of CKD development
among the OSA and non-OSA
cohort
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